Phase I/II study of bi-weekly XELIRI plus bevacizumab treatment in patients with metastatic colorectal cancer resistant to oxaliplatin-based first-line chemotherapy
作者: Tsunekazu MizushimaMutsumi FukunagaToshinori SuedaMasataka IkedaTakeshi KatoHo Min KimToshihiro KudoKohei MurataJunichi NishimuraTaishi HataChu MatsudaHirofumi YamamotoYuichiro DokiMasaki Mori
作者单位: 1Colorectal Group
2Osaka University Graduate School of Medicine
3Sakai City Medical Center
4Hyogo Prefectural Nishinomiya Hospital
5National Hospital Organization Osaka National Hospital
6Kansai Rosai Hospital
7Osaka Rosai Hospital
8Rinku General Medical Center
9Suita Municipal Hospital
刊名: Cancer Chemotherapy and Pharmacology, 2017, Vol.80 (1), pp.81-90
来源数据库: Springer Nature Journal
DOI: 10.1007/s00280-017-3336-3
关键词: CapecitabineIrinotecanBevacizumabColorectal cancerPhase I studyPhase II study
原始语种摘要: We aimed to determine the recommended dose for bi-weekly XELIRI plus bevacizumab for second-line chemotherapy and examined its safety and efficacy in patients with metastatic colorectal cancer resistant to oxaliplatin-based first-line chemotherapy.
全文获取路径: Springer Nature  (合作)
分享到:
来源刊物:
影响因子:2.795 (2012)

×
关键词翻译
关键词翻译
  • chemotherapy 化学疗法
  • weekly 每周的
  • resistant 耐久的
  • colorectal 结肠直肠的
  • metastatic 新陈代谢的
  • cancer 癌症
  • efficacy 效验
  • first 第一
  • treatment 处理
  • study 学习